Form 8-K Kite Pharma, Inc. For: Aug 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Outlook Therapeutics (OTLK) halted, news pending
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
Standpoint Research Starts Kite Pharma (KITE) at Buy
August 17, 2015 9:42 AM EDTStandpoint Research initiated coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $100.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $58.00 yesterday.
... More